Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Citigroup

Citigroup upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a neutral rating to a buy rating in a report released on Wednesday, MarketBeat.com reports. Citigroup currently has $700.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $600.00.

REGN has been the subject of a number of other reports. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 22nd. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research note on Monday, March 31st. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a research report on Wednesday, April 30th. Finally, Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $890.60.

Regeneron Pharmaceuticals Trading Down 0.5%

NASDAQ REGN opened at $571.36 on Wednesday. Regeneron Pharmaceuticals has a one year low of $520.50 and a one year high of $1,211.20. The company has a 50-day simple moving average of $605.64 and a 200-day simple moving average of $689.30. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a market capitalization of $62.46 billion, a PE ratio of 14.93, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the firm posted $9.55 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.62%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.96%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Landscape Capital Management L.L.C. acquired a new position in Regeneron Pharmaceuticals during the 1st quarter valued at $1,033,000. Orion Investment Co raised its stake in shares of Regeneron Pharmaceuticals by 2.3% in the 1st quarter. Orion Investment Co now owns 30,561 shares of the biopharmaceutical company’s stock valued at $19,383,000 after buying an additional 675 shares in the last quarter. Paces Ferry Wealth Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 14.8% in the 1st quarter. Paces Ferry Wealth Advisors LLC now owns 520 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 67 shares in the last quarter. CreativeOne Wealth LLC raised its stake in shares of Regeneron Pharmaceuticals by 16.6% in the 1st quarter. CreativeOne Wealth LLC now owns 520 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 74 shares in the last quarter. Finally, Ieq Capital LLC raised its stake in shares of Regeneron Pharmaceuticals by 114.1% in the 1st quarter. Ieq Capital LLC now owns 8,219 shares of the biopharmaceutical company’s stock valued at $5,213,000 after buying an additional 4,381 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.